Table 1.

COMPASS trial: outcomes comparing the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once-daily with aspirin 100 mg once-daily

Outcome	Rivaroxaban 2.5 mg twice-daily plus aspirin 100 mg once-daily vs. aspirin 100 mg once-daily N = 9152	Aspirin 100 mg once-daily N = 9126	HR (95% CI)
CV death, stroke, or myocardial infarction	379 (4.1%)	496 (5.4%)	0.76 (0.66–0.86)
CV death	160 (1.7)	203 (2.2%)	0.78 (0.64–0.96)
Stroke	83 (0.9%)	142 (1.6)	0.58 (0.44–0.76)
Myocardial infarction	178 (1.9%)	205 (2.2%)	0.86 (0.70–1.05)
Mortality	313 (3.4%)	378 (4.1%)	0.82 (0.71–0.96)
Venous thromboembolism	25 (0.3%)	41 (0.4%)	0.61 (0.37–1.00)
CV hospitalization	1303 (14.2%)	1394 (15.3%)	0.92 (0.86–1.00)